Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer and Onyx Pharmaceuticals have ended a late stage trial of Nexavar after analysis of the trial showed that the drug extended survival rates in patients with liver cancer.
Subscribe to our email newsletter
The analysis of the trial showed it met its primary endpoint resulting in superior overall survival in those patients receiving Nexavar tablets versus those patients receiving placebo. It was also noted that there was no demonstrated difference in serious adverse event rates between the two treatment arms.
Based on these positive conclusions, it was recommended that the trial be stopped early. Bayer and Onyx said it will stop the trial and allow all patients enrolled access to Nexavar.
“These results point to new potential treatment options for those patients suffering from this devastating disease,” commented Dr Josep Llovet, associate professor of Medicine/Director, HCC Research Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York.